Imaging Technology

NOVEMBER 7, 2024

tim.hodson Thu, 11/07/2024 - 11:25 Nov. 1, 2024 — The Centers for Medicare & Medicaid Services (CMS) have announced a significant adjustment to the Hospital Outpatient Prospective Payment System (HOPPS). Thursday, November 7, 2024 - 11:25 SNMMI offers special thanks to its partner organizations for their vital support.

Nuclear Medicine 97

Nuclear Medicine Radiopharmaceuticals Medicare Diagnostic 97

Imaging Technology

FEBRUARY 21, 2024

milla1cf Wed, 02/21/2024 - 18:58 February 21, 2024 — Blue Earth Therapeutics , a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, is pleased to share the publication of promising early clinical data with 177Lu-rhPSMA-10.1 Food and Drug Administration.

Clinic 104

Clinic Radiopharmaceuticals Nuclear Medicine Hospital 104

AuntMinnie

APRIL 15, 2024

decrease in hospital-based studies and a 2.5% increase in nonhospital-based studies, according to the newly published IMV 2024 NM Market Outlook Report. decrease in total procedures each year, with hospital-based procedures declining by 5.5% and non-hospital procedures increasing by 1.2%. Of these, 5.8 Nonhospitals 2.5%

Nuclear Medicine 111

Nuclear Medicine Hospital Radiopharmaceuticals Radiologist 111

AuntMinnie

JULY 12, 2024

As nuclear medicine therapies gain stature compared to nuclear medicine in diagnostic imaging, hospital administrators may be eyeing the potential of adding theranostics services. Reshaping the hospital's nuclear medicine and radiopharmaceutical strategy toward theranostics involves intensive and inclusive planning, Beyder explained at SNMMI.

Nuclear Medicine 105

Nuclear Medicine Radiation Oncology Radiopharmaceuticals Radiation 105

Imaging Technology

JANUARY 12, 2024

milla1cf Fri, 01/12/2024 - 11:09 January 12, 2024 — RefleXion Medical , Inc., CMS created two new reimbursement codes for use in the hospital outpatient setting, effective Jan. 1, 2024, to describe SCINTIX therapy. For more information: www.reflexion.com Friday, January 12, 2024 - 11:09

Radiopharmaceuticals 105

Radiopharmaceuticals Radiation Medicare Clinic 105

AuntMinnie

JUNE 11, 2024

TORONTO – The radiopharmaceutical Pluvicto improves progression-free survival in patients with metastatic prostate cancer who haven’t undergone taxane therapy, according to research presented at the SNMMI meeting. Oliver Sartor, MD The study, which was awarded SNMMI’s Abstract of the Year award, shared data from the phase III PSMAfore trial.

Nuclear Medicine 122

Nuclear Medicine Radiopharmaceuticals Radiograph Radiographer 122

Imaging Technology

JUNE 11, 2024

SNMMI introduced a new slate of officers during its 2024 Annual Meeting, held June 8-11 in Toronto. “As She will also raise awareness of nuclear medicine’s value to clinical colleagues and patients and will be laser-focused on breaking down barriers to radiopharmaceutical availability, reimbursement, affordability, and funding.

Nuclear Medicine 52

Nuclear Medicine Radiopharmaceuticals Patient Care Medical 52

AuntMinnie

NOVEMBER 1, 2024

In other radiology oriented provisions, the final rule also addresses payment for radiopharmaceuticals in physician offices. next year compared with average payment rates for most of 2024. Also, the finalized average payment rates under the MPFS will be reduced by 2.9%

Radiopharmaceuticals 85

Radiopharmaceuticals Medicare Computed Tomography Hospital 85

AuntMinnie

JUNE 3, 2024

With therapeutic radiopharmaceuticals coming to market quickly and available to smaller institutions around the U.S., My vision of a theranostic center includes a flagship facility that has a PET/CT scanner, a SPECT/CT scanner, and then multiple rooms for infusions of radiopharmaceuticals," Siegel explained.

Nuclear Medicine 105

Nuclear Medicine Radiopharmaceuticals Radiation Radiation Oncology 105

Imaging Technology

JULY 5, 2023

Ac-225 is a high energy alpha-emitting radioisotope of increasing interest for clinical studies investigating the use of targeted radiopharmaceutical therapy, which combines select molecules with therapeutic radioisotopes to directly target and deliver therapeutic doses of radiation to destroy cancer cells in patients with serious disease.

Medical 92

Medical Radiopharmaceuticals Pharmaceutical Radiation 92

Imaging Technology

AUGUST 31, 2023

milla1cf Thu, 08/31/2023 - 15:50 August 31, 2023 — NorthStar Medical Radioisotopes , LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals, and Curadh MTR Inc. Ac-225 for use in radiopharmaceutical therapy (RPT). actinium-225 (Ac-225). “As a company at the forefront of U.S.

Medical 98

Medical Radiopharmaceuticals Pharmaceutical Radiation 98

Imaging Technology

APRIL 3, 2023

Mr. Merrick continued, “Demand for therapeutic radiopharmaceuticals is increasing rapidly. NorthStar has further deepened and broadened our business platform with the recent establishment of a full-scale radiopharmaceutical CDMO/CMO services unit. Ac-225 using advanced, environmentally preferable electron accelerator technology.

Medical 98

Medical Radiopharmaceuticals Pharmaceutical Radiation 98

AuntMinnie

JULY 10, 2024

Centers for Medicare and Medicaid Services (CMS) proposed a new reimbursement plan July 10 for diagnostic PET scans that would provide separate payments for radiopharmaceuticals, as well as an extra payment for hospitals when they use domestically produced technetium-99m (Tc-99m).

Medicare 52

Medicare Nuclear Medicine Radiopharmaceuticals Imaging 52

Imaging Technology

APRIL 2, 2024

milla1cf Tue, 04/02/2024 - 18:51 April 2, 2024 — Less than three months after signing an agreement to acquire MIM Software Inc. , GE HealthCare Technologies Inc. iv See our latest earnings release dated February 6, 2024 for the definition of Adjusted EBIT. Journal of European Urology.

Healthcare 105

Healthcare Healthcare Radiation Oncology Magnetic Resonance Imaging 105

AuntMinnie

NOVEMBER 4, 2024

Centers for Medicare & Medicaid Services (CMS) 2025 Medicare Physician Fee Schedule (MPFS) and Hospital Outpatient Prospective Payment System (HOPPS) final rules. increase in the conversion factor from 2024, rising to $89.16 Although the 2025 MPFS calls for an overall 2.9% The adjusted HOPPS rule meanwhile will see a 2.9%

Radiation Oncology 80

Radiation Oncology Nuclear Medicine Medicare Radiation 80

Imaging Technology

JUNE 20, 2024

When produced in combination with the company’s TRACERcenter – which is designed to serve as a complete PET radiopharmacy solution – the resulting radiopharmaceuticals can help physicians identify and diagnose clinical signs across care areas – including oncology, cardiology, and neurology.

Healthcare 104

Healthcare Healthcare Nuclear Medicine Computed Tomography 104

AuntMinnie

APRIL 4, 2024

A decade ago, only a few radiopharmaceutical agents were used to help treat cancer patients. He also helped lead the theranostics conference at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2024 midwinter meeting. However, few freestanding theranostics centers exist today. Hope added.

Nuclear Medicine 88

Nuclear Medicine Radiation Oncology Nursing Radiation 88

AuntMinnie

JANUARY 19, 2024

For the hospital outpatient setting, Medicare currently packages the payment for radiopharmaceuticals into an overall payment for groupings of nuclear medicine procedures including PET. This has led to inadequate payment for precision radiopharmaceuticals and challenges for some providers seeking to offer these imaging services.

Disease 52

Disease Medicare Imaging PET Scan 52

AuntMinnie

MARCH 26, 2024

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval. Since the U.S.

Nuclear Medicine 122

Nuclear Medicine Radiopharmaceuticals Radiation Health Science 122

Imaging Technology

JUNE 10, 2024

milla1cf Mon, 06/10/2024 - 18:25 June 10, 2024 — Jean-Luc C. SNMMI introduced a new slate of officers during its 2024 Annual Meeting, held June 8-11 in Toronto. “As As SNMMI president-elect, I plan to focus on bringing and integrating radiopharmaceutical theranostics into the clinic to benefit as many patients as possible. “As

Nuclear Medicine 45

Nuclear Medicine Radiopharmaceuticals Health Science Hospital 45

AuntMinnie

JUNE 20, 2024

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval. Since the U.S.

Nuclear Medicine 52

Nuclear Medicine Radiopharmaceuticals Radiation Health Science 52

AuntMinnie

JUNE 9, 2024

As SNMMI president-elect, I plan to focus on bringing and integrating radiopharmaceutical theranostics into the clinic to benefit as many patients as possible," Urbain said in an SNMMI announcement. He currently serves as a staff physician at Stratford General Hospitals in Ontario, in addition to his consulting and academic center activities.

Nuclear Medicine 40

Nuclear Medicine Radiopharmaceuticals Government Education 40